Biomarkers selected for analysis
| Pathobiological function | |
|---|---|
| The biomarkers were selected from clusters statistically associated with the diagnosis of COPD and thought to have known or potential significance in the pathobiology of COPD. | |
| AR, amphiregulin; BDNF, brain-derived neurotrophic factor; βNGF, β-nerve growth factor; IFNγ, interferon γ; IL, interleukin; IL-1ra, interleukin 1 receptor antagonist; IL-2Rγ, interleukin 2 receptor gamma; I-TAC, interferon γ-inducible T cell α chemoattractant; MCP-1, monocyte chemotactic protein 1; MIP-1β, macrophage inflammatory protein 1β; MMP-9, matrix metalloproteinase 9; MPIF-1, myeloid progenitor inhibitory factor 1; PAI-II, plasminogen activator inhibitor II; TGFα, transforming growth factor α; TIMP-1, tissue inhibitors of metalloproteinases 1; TNFα, tumour necrosis factor α; TNF R1, tumour necrosis factor receptor I; VEGF, vascular endothelial growth factor. | |
| Chemoattractants | I-TAC, eotaxin-2, MPIF-1, MCP-1, MIP-1β, IL-8, PARC |
| Inflammation | IL-15, IL-1ra, IL-17, TNFα, TNF R1, IFNγ, IL-12 p40, IL-2Rγ |
| Destruction and repair | TGFα, VEGF, AR, BDNF, βNGF, MMP-9, TIMP-1 |
| Novel markers | PAI-II, prolactin |